Cargando…

Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study

There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Umemura, Takumi, Mutoh, Yoshikazu, Mizuno, Takahito, Hagihara, Mao, Kato, Hideo, Yamada, Tetsuya, Ikeda, Yoshiaki, Mikamo, Hiroshige, Ichihara, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691069/
https://www.ncbi.nlm.nih.gov/pubmed/36421623
http://dx.doi.org/10.3390/healthcare10112299
_version_ 1784836952783060992
author Umemura, Takumi
Mutoh, Yoshikazu
Mizuno, Takahito
Hagihara, Mao
Kato, Hideo
Yamada, Tetsuya
Ikeda, Yoshiaki
Mikamo, Hiroshige
Ichihara, Toshihiko
author_facet Umemura, Takumi
Mutoh, Yoshikazu
Mizuno, Takahito
Hagihara, Mao
Kato, Hideo
Yamada, Tetsuya
Ikeda, Yoshiaki
Mikamo, Hiroshige
Ichihara, Toshihiko
author_sort Umemura, Takumi
collection PubMed
description There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between March 2020 and April 2022 at Tosei General Hospital, Japan. Propensity score matching was performed between patients with eGFR ≤ 30 mL/min and eGFR >30 mL/min with remdesivir administration. The primary outcome was 30-day mortality after the first administration. Adverse events, including development of acute kidney injury (AKI), liver function disorder, anemia, and thrombocytopenia 48 h after the end of remdesivir administration, were evaluated. After propensity score matching, 23 patients were selected from each group. There were no differences in the 30-day mortality (risk ratio [RR] 1.00; 95% confidence interval [CI] 0.18–5.56). Development of AKI and liver function disorder was not statistically different between the two groups (RR 1.05; 95% CI 0.96–1.14 and RR 0.48; 95% CI 0.04–5.66, respectively). There was no trend toward a significant increase in adverse events in the eGFR < 30 mL/min group and severe renal dysfunction had little effect on the safety of remdesivir treatment.
format Online
Article
Text
id pubmed-9691069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96910692022-11-25 Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study Umemura, Takumi Mutoh, Yoshikazu Mizuno, Takahito Hagihara, Mao Kato, Hideo Yamada, Tetsuya Ikeda, Yoshiaki Mikamo, Hiroshige Ichihara, Toshihiko Healthcare (Basel) Brief Report There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between March 2020 and April 2022 at Tosei General Hospital, Japan. Propensity score matching was performed between patients with eGFR ≤ 30 mL/min and eGFR >30 mL/min with remdesivir administration. The primary outcome was 30-day mortality after the first administration. Adverse events, including development of acute kidney injury (AKI), liver function disorder, anemia, and thrombocytopenia 48 h after the end of remdesivir administration, were evaluated. After propensity score matching, 23 patients were selected from each group. There were no differences in the 30-day mortality (risk ratio [RR] 1.00; 95% confidence interval [CI] 0.18–5.56). Development of AKI and liver function disorder was not statistically different between the two groups (RR 1.05; 95% CI 0.96–1.14 and RR 0.48; 95% CI 0.04–5.66, respectively). There was no trend toward a significant increase in adverse events in the eGFR < 30 mL/min group and severe renal dysfunction had little effect on the safety of remdesivir treatment. MDPI 2022-11-17 /pmc/articles/PMC9691069/ /pubmed/36421623 http://dx.doi.org/10.3390/healthcare10112299 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Umemura, Takumi
Mutoh, Yoshikazu
Mizuno, Takahito
Hagihara, Mao
Kato, Hideo
Yamada, Tetsuya
Ikeda, Yoshiaki
Mikamo, Hiroshige
Ichihara, Toshihiko
Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
title Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
title_full Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
title_fullStr Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
title_full_unstemmed Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
title_short Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
title_sort safety evaluation of remdesivir for covid-19 patients with egfr < 30 ml/min without renal replacement therapy in a japanese single-center study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691069/
https://www.ncbi.nlm.nih.gov/pubmed/36421623
http://dx.doi.org/10.3390/healthcare10112299
work_keys_str_mv AT umemuratakumi safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT mutohyoshikazu safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT mizunotakahito safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT hagiharamao safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT katohideo safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT yamadatetsuya safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT ikedayoshiaki safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT mikamohiroshige safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy
AT ichiharatoshihiko safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy